Intranasal immunotherapy and polymerized grass pollen allergens.

Area of Science:

• Allergy and Immunology
• Immunotherapy Research
• Respiratory Medicine

Background:

• Hay fever, or allergic rhinitis, affects millions globally, necessitating effective treatments.
• Current immunotherapy options require further optimization for sustained efficacy.
• Modified allergens offer a potential strategy to improve immunotherapy outcomes.

Purpose of the Study:

• To evaluate the efficacy of intranasal immunotherapy using glutaraldehyde-modified Lolium perenne allergens (Glu-Rye) in adults with hay fever.
• To assess the impact of Glu-Rye treatment on nasal sensitivity to allergens.
• To determine the duration of treatment effects on nasal sensitivity and IgE antibody levels.

Main Methods:

• A stratified placebo-controlled trial involving 16 adult subjects with hay fever.
• Intranasal preseasonal administration of Glu-Rye or placebo over 10 weeks.
• Quantitative nasal challenge tests and posterior rhinometry to measure nasal sensitivity and airway resistance.
• Measurement of serum IgE antibody levels to L. perenne pre- and post-treatment.

Main Results:

• A 10-week course of intranasal Glu-Rye treatment led to a reduction in nasal sensitivity to L. perenne allergens.
• This reduction in nasal sensitivity was not maintained when tested 9 months after treatment cessation.
• Post-seasonal serum IgE antibody levels to L. perenne showed no significant alteration following Glu-Rye treatment.

Conclusions:

• Intranasal immunotherapy with Glu-Rye demonstrated a transient decrease in nasal allergen sensitivity.
• The immunotherapeutic effect of Glu-Rye was short-lived, indicating a need for further research into sustained delivery or alternative modification strategies.
• Glu-Rye immunotherapy did not significantly impact systemic IgE responses to L. perenne allergens.